A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China

Inclusion Criteria: * Participant who is in compliance with eligibility for adalimumab based on the local label; * Moderate to severe plaque psoriasis patients eligible to use adalimumab according to the local label without any contraindication * Patients have signed the authorization (or informed consent where applicable) to disclose and use personal health information after been prescribed with adalimumab. Exclusion Criteria: * Patients who are pregnant or breast feeding at enrolment or wish to become pregnant during the following adalimumab treatment and within 150 days since adalimumab discontinuation; * Patients in any psoriasis related clinical trial at the time of enrolment, at baseline or at any point during the study follow-up; * Patients with active tuberculosis or other severe infections (e.g. sepsis and opportunistic infections) as well as moderate to severe cardiac insufficiency. * Patients with difficulties for adequately reading, understanding and completing patient questionnaires.